Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU

 Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU

Shots:

  • The EC’s MAA is based on the P-III APPROACH study results assessing of Waylivra vs PBO in 66 patients with FCS and the ongoing APPROACH OLE study and is supported by P-III COMPASS study results
  • The P-III APPROACH study resulted in the reduction in triglyceride levels (77% vs 18%) with a reduction in apoC-III by 84% and were published in the August 8th issue of the NEJM entitled “Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.”
  • Waylivra is the only therapy and is based on Ionis’ antisense technology act by reducing the production of apoC-III, thus regulating plasma triglycerides. Akcea is working to confirm a path forward for WAYLIVRA in the US and Canada

Click here to­ read full press release/ article | Ref: Akcea Therapeutics | Image: Pharma Journalist

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post